GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (NAS:ARNA) » Definitions » Operating Income

Arena Pharmaceuticals (Arena Pharmaceuticals) Operating Income : $-554.29 Mil (TTM As of Dec. 2021)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Operating Income?

Arena Pharmaceuticals's Operating Income for the three months ended in Dec. 2021 was $-153.43 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2021 was $-554.29 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Arena Pharmaceuticals's Operating Income for the three months ended in Dec. 2021 was $-153.43 Mil. Arena Pharmaceuticals's Revenue for the three months ended in Dec. 2021 was $0.05 Mil. Therefore, Arena Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2021 was -284,120.37%.

Arena Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Arena Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2021 was -341.59%. Arena Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -3,197.39%.


Arena Pharmaceuticals Operating Income Historical Data

The historical data trend for Arena Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Operating Income Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -79.99 -144.78 482.75 -426.62 -554.29

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -135.30 -132.04 -144.35 -124.48 -153.43

Arena Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-554.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arena Pharmaceuticals  (NAS:ARNA) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Arena Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2021 is calculated as:

ROC % (Q: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2021 ) + Invested Capital (Q: Dec. 2021 ))/ count )
=-613.7 * ( 1 - 0% )/( (130.869 + 228.454)/ 2 )
=-613.7/179.6615
=-341.59 %

where

Invested Capital(Q: Sep. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=901.027 - 32.593 - ( 771.667 - max(0, 53.355 - 790.92+771.667))
=130.869

Invested Capital(Q: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=784.705 - 53.102 - ( 550.469 - max(0, 66.316 - 569.465+550.469))
=228.454

Note: The Operating Income data used here is four times the quarterly (Dec. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Arena Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2021  Q: Dec. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-618.424/( ( (19.558 + max(-29.218, 0)) + (19.125 + max(-42.268, 0)) )/ 2 )
=-618.424/( ( 19.558 + 19.125 )/ 2 )
=-618.424/19.3415
=-3,197.39 %

where Working Capital is:

Working Capital(Q: Sep. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 19.253) - (32.593 + 0 + 15.878)
=-29.218

Working Capital(Q: Dec. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 18.996) - (53.102 + 0 + 8.162)
=-42.268

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2021) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Arena Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2021 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2021 )/Revenue (Q: Dec. 2021 )
=-153.425/0.054
=-284,120.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Arena Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Executives
Amit Munshi director, officer: President and CEO C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Robert Lisicki officer: EVP, Chief Commercial Officer C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Dallas Jayson Donald Alexander director AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Vincent Aurentz officer: Executive VP and CBO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Christopher Cabell officer: EVP, Head of R&D, and CMO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Oliver Fetzer director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Laurie Stelzer officer: EVP & Chief Financial Officer 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Joan Schmidt officer: EVP, General Counsel & Sec C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Kevin Robert Lind officer: Executive VP and CFO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121